{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:42:40Z","timestamp":1787010160616,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"41","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,14]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>LCZ696 is a novel neuroendocrine inhibitor that has been widely used in heart failure (HF). However, its advantage over other neuroendocrine inhibitors, such as angiotensin-converting enzyme inhibitors (ACEis) and angiotensin-receptor blockers (ARBs) has not been fully elucidated. This study aimed to provide the latest evidence regarding the efficacy and safety of LCZ696 as compared to other ACEis and ARBs with regards to the treatment of HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We systematically searched databases, including PubMed, Embase, and the Cochrane Library, for relevant randomized controlled trials (RCTs). The outcome measures included all-cause mortality, rate of hospitalizations for HF, rate of death from cardiovascular causes, change in N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, and decline of renal function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Five RCTs involving 19,078 patients were identified. The meta-analysis indicated that LCZ696 was associated with a significant reduction in all-cause mortality (hazard ratio [HR]\u2005=\u20050.84; 95% confidence interval [CI], 0.76\u20130.93;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.0005), rate of hospitalizations for HF (HR\u2005=\u20050.80; 95% CI, 0.73\u20130.87;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.00001), reduction in NT-proBNP levels (rate ratio\u2005=\u20050.78; 95% CI, 0.70\u20130.88;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.0001), and decline in renal function (odds ratio\u2005=\u20050.77; 95% CI, 0.68\u20130.88;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.0001) compared with ACEis and ARBs. However, there was no statistical difference in the rate of death from cardiovascular causes (HR\u2005=\u20050.86; 95% CI, 0.72\u20131.03;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.09) between LCZ696 and ACEis and ARBs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>LCZ696 is superior to ACEis and ARBs in the treatment of HF. Hence, it should be more widely used clinically.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000030904","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T19:09:07Z","timestamp":1665774547000},"page":"e30904","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["The angiotensin receptor and neprilysin inhibitor, LCZ696, in heart failure: A meta-analysis of randomized controlled trials"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-8897","authenticated-orcid":false,"given":"Yan","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Geriatrics, Wuxiang Branch of Nanning Second People\u2019s Hospital, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"He","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Wuxiang Branch of Nanning Second People\u2019s Hospital, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dun-Chang","family":"Mo","sequence":"additional","affiliation":[{"name":"Radiotherapy Department, Nanning Second People\u2019s Hospital, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Chen","sequence":"additional","affiliation":[{"name":"ENT & HN Surgery Department, Nanning Second People\u2019s Hospital, Nanning, Guangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Lu","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Wuxiang Branch of Nanning Second People\u2019s Hospital, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Xing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Wuxiang Branch of Nanning Second People\u2019s Hospital, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Wuxiang Branch of Nanning Second People\u2019s Hospital, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/S0140-6736(05)66621-4","article-title":"Heart failure.","volume":"365","author":"McMurray","year":"2005","journal-title":"Lancet"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41572-020-0151-7","article-title":"Acute heart failure.","volume":"6","author":"Arrigo","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/j.2040-4603.2016.tb00669.x","article-title":"Pathophysiology of heart failure.","volume":"6","author":"Tanai","year":"2015","journal-title":"Compr Physiol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41569-020-0363-2","article-title":"Evaluation and management of heart failure with preserved ejection fraction.","volume":"17","author":"Borlaug","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/ehf2.12555","article-title":"Highlights in heart failure.","volume":"6","author":"Tomasoni","year":"2019","journal-title":"ESC Heart Fail"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0735-1097(99)00439-8","article-title":"Nonadherence with angiotensin-converting enzyme inhibitor therapy: a comparison of different ways of measuring it in patients with chronic heart failure.","volume":"34","author":"Struthers","year":"1999","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 12","key":"R7-20250504","first-page":"S273","article-title":"Angiotensin receptor blockers: pharmacology and clinical significance.","volume":"10","author":"Mimran","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ejhf.250","article-title":"Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.","volume":"17","author":"McMurray","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1090.e1","DOI":"10.1016\/j.amjmed.2007.02.029","article-title":"Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy.","volume":"120","author":"Jneid","year":"2007","journal-title":"Am J Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/bcpt.12453","article-title":"LCZ696 (Valsartan\/Sacubitril)--a possible new treatment for hypertension and heart failure.","volume":"118","author":"Andersen","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10741-018-9757-1","article-title":"Practical guidance on the use of sacubitril\/valsartan for heart failure.","volume":"24","author":"Sauer","year":"2019","journal-title":"Heart Fail Rev"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","article-title":"Combined angiotensin receptor antagonism and neprilysin inhibition.","volume":"133","author":"Hubers","year":"2016","journal-title":"Circulation"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.hfc.2019.08.010","article-title":"The cardiorenal syndrome in heart failure.","volume":"16","author":"Costanzo","year":"2019","journal-title":"Heart Fail Clin"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchf.2020.08.014","article-title":"Cardiovascular and renal outcomes of mineralocorticoid receptor antagonist use in PARAGON-HF.","volume":"9","author":"Jering","year":"2021","journal-title":"JACC Heart Fail"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction.","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure.","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure.","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1001\/jama.2021.18463","article-title":"Effect of sacubitril\/valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial.","volume":"326","author":"Pieske","year":"2021","journal-title":"JAMA"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.","volume":"380","author":"Solomon","journal-title":"Lancet"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction.","volume":"73","author":"Greene","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry.","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.mcna.2014.01.002","article-title":"Evaluation and treatment of chronic cough.","volume":"98","author":"Terasaki","year":"2014","journal-title":"Med Clin North Am"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"e37396","DOI":"10.1371\/journal.pone.0037396","article-title":"Angiotensin-converting enzyme (ACE) gene insertion\/deletion polymorphism and ACE inhibitor-related cough: a meta-analysis.","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ejhf.548","article-title":"Initiating sacubitril\/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens.","volume":"18","author":"Senni","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1136\/heartjnl-2017-311295","article-title":"Sacubitril\/valsartan: beyond natriuretic peptides.","volume":"103","author":"Singh","year":"2017","journal-title":"Heart"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/FJC.0000000000001049","article-title":"Adverse events of sacubitril\/valsartan: a meta-analysis of randomized controlled trials.","volume":"78","author":"Huang","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"173444","DOI":"10.1016\/j.ejphar.2020.173444","article-title":"Effects of sacubitril\/valsartan in patients with heart failure and chronic kidney disease: a meta-analysis.","volume":"884","author":"Kang","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"113","DOI":"10.31083\/j.rcm.2020.01.2","article-title":"LCZ696 and preservation of renal function in heart failure: a meta-analysis of 6 randomized trials.","volume":"21","author":"Chen","year":"2020","journal-title":"Rev Cardiovasc Med"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jacc.2021.07.045","article-title":"NT-proBNP response to heart failure therapies: an imperfect surrogate.","volume":"78","author":"Cunningham","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1042\/CS20150469","article-title":"The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment.","volume":"130","author":"Volpe","year":"2016","journal-title":"Clin Sci (Lond)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030904","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:27:52Z","timestamp":1746322072000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":31,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000030904","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]}}}